摘要
目的:观察雷珠单抗玻璃体腔注射联合眼底激光治疗糖尿病性黄斑水肿的效果。方法:选取本院收治的糖尿病性黄斑水肿患者700例(700眼),按照随机数字表法分为对照组、试验组,各350例(350眼)。对照组给予激光光凝治疗,试验组在对照组基础上加用雷珠单抗玻璃体腔注射。比较两组黄斑水肿消退情况、最佳矫正视力及并发症情况。结果:治疗后,试验组水肿消退95.14%,高于对照组的90.86%(P<0.05);试验组视力提高、视力不变发生率均高于对照组,视力下降发生率低于对照组,差异均有统计学意义(P<0.05);试验组并发症发生率为3.43%,显著低于对照组的8.86%(P<0.05)。结论:相比单纯使用激光光凝治疗,雷珠单抗玻璃体腔注射联合眼底激光治疗糖尿病性黄斑水肿的疗效显著,可快速有效地吸收黄斑水肿,提高患者视力水平,降低并发症发生率,值得在临床上推广使用。
Objective:To observe the effect of intravitreal injection of Ranibizumab combined with fundus laser in treatment of diabetic macular edema.Method:A total of 700 patients(700 eyes)with diabetic macular edema admitted to our hospital were selected.According to the random number table method,they were divided into control group and experimental group,350 cases(350 eyes)in each group.The control group was treated with laser photocoagulation,and the experimental group was treated with intravitreal injection of Ranibizumab on the basis of the control group.The regression of macular edema,best corrected visual acuity and complications were compared between the two groups.Result:After treatment,edema subsided by 95.14%in the experimental group,which was higher than 90.86%in the control group(P<0.05).The incidence of visual acuity improvement and visual acuity invariability in the experimental group were higher than those in the control group,and the incidence of visual acuity decline was lower than that in the control group,the differences were statistically significant(P<0.05).The incidence of complications in the experimental group was 3.43%,which was significantly lower than 8.86%in the control group(P<0.05).Conclusion:Compared with laser photocoagulation alone,Ranibizumab intravitreal injection combined with fundus laser is effective in treatment of diabetic macular edema,it can absorb macular edema quickly and effectively,improve the visual acuity of patients,and reduce the incidence of complications,which is worth popularizing in clinical practice.
作者
王江敏
李东正
王君辉
WANG Jiangmin;LI Dongzheng;WANG Junhui(Sanmenxia Hospital of the Yellow River, Sanmenxia 472000, China)
出处
《中国医学创新》
CAS
2019年第30期58-61,共4页
Medical Innovation of China